- Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitorEli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs, saying it would spend as much asEndpoints · 3mo ago↗ source
- Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trialA year after it reported a Phase 2/3 success, Compass Therapeutics on Monday revealed further results for its closely watched bispecific antibody in second-line biliary tract cancer. While the in…Endpoints · 3mo ago↗ source
- Intellia's in vivo CRISPR therapy first to succeed in Phase 3An experimental treatment that uses CRISPR to edit genes directly inside the body has just succeeded in a Phase 3 trial — a first for the technology — putting it on track for a potential FDA approv…